Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Short-term Investments (2020 - 2023)

ProQR Therapeutics' Short-term Investments history spans 4 years, with the latest figure at $277590.6 for Q3 2023.

  • On a quarterly basis, Short-term Investments rose 91.19% to $277590.6 in Q3 2023 year-over-year; TTM through Sep 2023 was $277590.6, a 91.19% increase, with the full-year FY2022 number at $1.3 million, down 72.74% from a year prior.
  • Short-term Investments hit $277590.6 in Q3 2023 for ProQR Therapeutics, down from $405079.9 in the prior quarter.
  • Over the last five years, Short-term Investments for PRQR hit a ceiling of $4.6 million in Q4 2021 and a floor of $1934.8 in Q1 2021.
  • Historically, Short-term Investments has averaged $1.1 million across 4 years, with a median of $520785.8 in 2023.
  • The widest YoY moves for Short-term Investments: up 16084.19% in 2022, down 94.56% in 2022.
  • Tracing PRQR's Short-term Investments over 4 years: stood at $1.0 million in 2020, then soared by 356.87% to $4.6 million in 2021, then crashed by 71.8% to $1.3 million in 2022, then tumbled by 78.46% to $277590.6 in 2023.
  • Business Quant data shows Short-term Investments for PRQR at $277590.6 in Q3 2023, $405079.9 in Q2 2023, and $636491.7 in Q1 2023.